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From drug repurposing studies, this work aimed to evaluate the activity of different pyrazinoic acid 
(POA) derivatives against Sporothrix brasiliensis. The POA esters were prepared and characterized 
as previously reported by classical esterification reactions, with good to excellent yields. Sporothrix 
brasiliensis isolates from cats (n=6) and standard strains of S. brasiliensis and S. schenckii were used to 
assess the antifungal activity of the POA derivatives through broth microdilution assay (CLSI M38-A2). 
Among the tested compounds, molecules 3 and 4 showed fungistatic and fungicidal activities against 
all Sporothrix spp. strains, and the obtained MIC and MFC values ranged from 2.12 to 4.24 mg/mL and 
from 1.29 to 5.15 mg/mL, respectively. Compound 2 and 5 were active as in vitro inhibitors of fungal 
growth, but showed weak fungicidal activity, while molecules 1 and POA itself were inactive. The results 
suggest the activity of POA derivatives against Sporothrix spp. may be dependent on the lipophilicity. 
In addition, the antifungal susceptibility of the isolates to itraconazole was performed, showing that 
two Sporothrix isolates from cats were itraconazole-resistant. Compounds 3 and 4 were also active 
against these itraconazole-resistant isolates, indicating a possible alternative route to the standard mode 
of action of itraconazole. 
Keywords: Sporotrichosis. Sporothrix schenckii complex. Itraconazole. Antifungal resistance. Prodrugs. 
Pyrazinoic acid derivatives.
INTRODUCTION
Among the zoonotic diseases with importance in 
human and veterinary medicine, sporotrichosis should be 
highlighted due to the increasing reports in both human 
and animals. This infection is clinically characterized by 
subcutaneous nodules, ulcers and crusts, which can spread 
to systemic organs (Madrid et al., 2012). This mycosis 
is caused by agents of Sporothrix schenckii complex 
(Marimon et al., 2007) through the cutaneous inoculation 
by contaminated plant material (De Araújo et al., 2015) 
or by bite and scratch of animals, especially sick cats 
(Madrid et al., 2012; Montenegro et al., 2014; Rodrigues 
et al., 2014a). In Brazil, S. brasiliensis is prevalent in 
feline outbreaks and is considered one of the most virulent 
species (Montenegro et al., 2014; Rodrigues et al., 2014a).
Recently, the emergence of antifungal resistance 
has made the therapeutic control of the disease in animals 
more difficult (Rodrigues et al., 2014a; Borba-Santos et 
al., 2015; Waller et al., 2016), and has encouraged the 
search for new molecules with antifungal potential. With 
this regard, drug repurposing (or also called repositioning) 
is an approach that is frequently under consideration to 
find novel therapeutic options to diseases in the urgent 
state. The drug repurposing approach is based on study 
known drugs that are already approved for some disease 
or condition to treat another. Classical drug discovery and 
development pipeline is a slow and expensive process to 
find a new chemical entity (NCE), which includes the 
clinical trials, registry and several other processes to reach 
the patients. A large number of these NCEs never reach the 
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clinical trials, and some other does not get the approval 
after that (Corsello et al., 2017). 
In this panorama, repositioning is advantageous 
since the data from the NCE is already available from 
the approved drug. This is the main reason why this 
approach can speed up the translation of the active agent 
from the bench to the patient (Ashburn, Thor, 2004). The 
most famous example of successful repositioning of a 
drug is certainly the discovery of sildenafil (Viagra) to 
erectile dysfunction, which was before evaluated as a 
cardiovascular agent.
Pyrazinoic acid (POA) is  a  widely known 
antimycobacterial agent. It is proposed that POA is 
the active form of pyrazinamide (PZA), a first-class 
antimycobacterial drug used in human tuberculosis 
(Figure 1). The mechanism of action of both PZA and 
POA is not totally understood, but it depends firstly on the 
activation of PZA by a pyrazinamidase (PZAse) (Zhang 
et al., 2003). PZA also demonstrated to inhibit the fatty 
acid synthase I (FASI) in the NADPH binding site by 
competition (Zimhony et al., 2000). POA itself shows poor 
antimycobacterial activity due to its poor penetration into 
mycobacteria, and thus POA esters with better penetration 
were reported as options to circumvent this issue. 
POA esters have shown good antimycobacterial 
activity in vitro against PZA-sensitive and resistant 
strains of Mycobacterium tuberculosis (Fernandes 
et al., 2014; Segretti et al., 2016). Furthermore, a 
repurposing study for PZA against Leishmania was 
reported (Mendez et al., 2009), showing the potential 
of these antimycobacterial compounds in affect other 
microorganisms, such as Leishmania major. However, 
none repurposing studies to POA derivatives were 
reported to date. Considering the repurposing strategy, 
the urgency of a novel therapeutic to sporotrichosis 
and the absence of literature information regarding the 
activity of POA derivatives against fungi, the aim of 
this study was to evaluate the activity of different POA 
derivatives against Sporothrix brasiliensis. 
MATERIAL AND METHODS
Material
Chemical reagents for the preparation of the 
compounds were purchased from commercial sources 
in an adequate purity and used without prior treatment. 
1H and 13C NMR spectra were recorded in a Bruker 
Ultrashield 300 spectrometer, operating at 300 MHz 
and 75 MHz, respectively, using CDCl3 as a solvent 
with tetramethylsilane (TMS) as an internal standard. 
Chemical shifts are reported in parts per million (ppm, 
δ units). Coupling constants (J) are reported in units of 
hertz (Hz), if applicable. The NMR data is in accordance 
with previous reports in the literature. Culture medium 
of Potato-dextrose agar and Sabouraud dextrose-agar 
(Kasvi, Liofilchem®, Italy) were used for fungal growth. 
For antifungal testing, the RPMI-1640 (Roswell Park 
Memorial Institute, Gibco®, Life Technologies Co., 
United States) was prepared as liquid medium with 
addition of MOPS [3-(N-morpholino propanesulfonic 
acid)] (Alamar Tecno-Científica Ltda, Brazil), and 
itraconazole was purchased from pharmaceutical industry 
(Sporanox®, Janssen-Pharmaceutica Ltda, Belgium).
Preparation of the molecules 1–4
In a round-bottom flask, 5 mmol of POA (0.620 g) 
were dissolved in 10 mL of appropriate alcohol (methanol, 
ethanol, butanol or 2-chloroethanol for compounds 1-4, 
respectively), and 7 mmol of thionyl chloride (~0.5 mL) 
were added. The mixture was then heated to 60 °C and 
stirred overnight. The solvent was evaporated, and the 
oily residue was taken up in 10 mL of ethyl acetate and 
washed twice with 10 mL of saturated aqueous NaHCO3, 
and 10 mL of brine. The organic phase was dried using 
anhydrous Na2SO4, and the solvent was evaporated. Methyl 
pyrazinoate (1), 80% yield. 1H-NMR (CDCl3, 300 MHz, 
δ = ppm) 4.07 (s, 3H), 8.75 (dd, J = 2.4, 1.4 Hz, 1H), 8.80 
FIGURE 1 – Illustration of the mechanism of action of the pyrazinoic acid (POA) prodrugs, which POA itself cannot penetrate the 
mycobacterial membranes, whereas pyrazinamide (PZA) is activated to pyrazinoic acid (POA) inside mycobacteria.
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(d, J = 2.4 Hz, 1H), 9.35 (d, J = 1.4 Hz, 1H). 13C-NMR 
(CDCl3, 75 MHz, δ = ppm) 53.2, 143.4, 144.4, 146.3, 147.8, 
164.4. Ethyl pyrazinoate (2), 77% yield. 1H-NMR (CDCl3, 
300 MHz, δ = ppm) 1.47 (t, J = 7.1 Hz, 3H), 4.53 (q, J = 7.1 
Hz, 2H), 8.74 (dd, J = 2.4, 1.4 Hz, 1H), 8.78 (d, J = 2.4 Hz, 
1H), 9.33 (d, J = 1.4 Hz, 1H). 13C-NMR (CDCl3, 75 MHz, 
δ = ppm) 14.3, 62.5, 143.7, 144.5, 146.4, 147.7, 164.0. Butyl 
pyrazinoate (3), 60% yield. 1H-NMR (CDCl3, 300 MHz, 
δ = ppm) 0.99 (t, J = 7.4 Hz, 3H), 1.49 (sext, J = 7.4 Hz, 2H), 
1.83 (quint, J = 7.1 Hz, 2H), 8.75 (dd, J = 2.4, 1.4 Hz, 1H), 
8.78 (d, J = 2.4 Hz, 1H), 9.33 (d, J = 1.4 Hz, 1H). 13C-NMR 
(CDCl3, 75 MHz, δ = ppm) 13.8, 19.2, 30.6, 66.3, 143.6, 
144.5, 146.3, 147.6, 164.0. 2-Chloroethyl pyrazinoate (4), 
85% yield. 1H-NMR (CDCl3, 300 MHz, δ = ppm) 3.95 (t, 
J = 5.6 Hz, 2H), 4.75 (t, J = 5.6 Hz, 2H), 8.82 (dd, J = 2.4, 
1.4 Hz, 1H), 8.87 (d, J = 2.4 Hz, 1H), 9.34 (d, J = 1.4 Hz, 
1H). 13C-NMR (CDCl3, 75 MHz, δ = ppm) 41.2, 65.5, 143.1, 
144.6, 146.4, 148.0, 163.5.
Preparation of the molecule 5
In a round-bottom flask, 12 mmol of POA (1.488 g) 
were dissolved in 10 mL of acetonitrile, when 5 mmol of 
1,2-dibromoethane (0.940 g) and 10 mmol of triethylamine 
(1.100 g) were added. The reaction mixture was stirred 
under reflux for 12 h, and the solvent was then evaporated. 
The residue was taken up in 10 mL of ethyl acetate, and 
washed twice with 10 mL of aqueous NaHCO3, and 
10 mL of distilled water. The organic layer was dried 
using anhydrous Na2SO4, and the solvent was evaporated. 
The crude product was purified using flash column 
chromatography, using a hexane-ethyl acetate gradient 
as eluent. 2-(Pyrazinoyloxy)-ethyl pyrazinoate (5), 40% 
yield. 1H-NMR (CDCl3, 300 MHz, δ = ppm) 4.85 (s, 4H), 
8.74 (dd, J = 2.4, 1.5 Hz, 2H), 8.78 (d, J = 2.4 Hz, 2H), 9.32 
(d, J = 1.5 Hz, 2H). 13C-NMR (CDCl3, 75 MHz, δ = ppm) 
63.6, 143.0, 144.5, 146.5, 148.0, 163.8.
Anti-Sporothrix spp. activity
For in vitro tests, S. brasiliensis clinical isolates 
(n=6) obtained from cats with sporotrichosis in Pelotas/
RS (codes S68, S120, S141, S144 and S146) and São 
Lourenço do Sul/RS (code S119), which both cities are 
located in southern Brazil, were used, as well as standard 
strains from human sporotrichosis by S. brasiliensis (Ss 
177, also identified as IPEC 16919 from Instituto de 
Pesquisa Clínica Evandro Chagas, FIOCRUZ, Brazil) 
and S. schenckii sensu stricto (Ss 126), totaling eight 
fungal isolates. All isolates were molecularly identified 
at Laboratório de Micologia Médica Molecular (Federal 
University of São Paulo, Brazil) by PCR-restriction 
fragment length polymorphism analysis (Rodrigues, de 
Hoog, de Camargo, 2014b). The in vitro antifungal test 
was performed using the broth microdilution method, 
according to the CLSI M38-A2 standard protocol 
(NCCLS, 2008). 
The fungal inoculum was prepared from colonies 
grown in mycelial phase on potato-dextrose agar at 27 °C 
for seven days. Saline solution (2 mL) with Tween 80 (1%) 
was added to the surface of each colony and the fungal 
content was scraped with a scalpel blade to collect filament 
cells and conidia. The fungal content was transferred and 
suspended in tubes containing sterile saline, and adjusted 
to 1.0 McFarland scale and, subsequently, in an ultraviolet 
(UV)-visible spectrophotometer (Spectrum Instruments 
Co.) with transmittance adjusted to 80-82% at the fixed 
wavelength of 530 nm. Suspensions were diluted in RPMI-
1640 medium buffered with 2% glucose and MOPS at 
1:50, v/v). The molecules were prepared in RPMI-1640 
(1.6 mL) and DMSO (0.05 mL) to promote their dilution. 
From the initial concentration, ten serial dilutions were 
performed on RPMI-1640 medium buffered with MOPS 
directly on microplates to obtain a final concentration of 
3.35–0.006 mg/mL (1); 3.06–0.006 mg/mL (2); 4.24–
0.008 mg/mL (3); 5.15–0.01 mg/mL (4); 2.9–0.005 mg/
mL (5) and 3.18–0.006 mg/mL (POA).
Fungal suspension (100 μl) was added in all tested 
wells, including in the positive control. Extract suspensions 
diluted in RPMI-1640 were used as negative control. 
Positive control consisted in RPMI-1640 with fungal 
suspension. For itraconazole preparation, the internal 
content was diluted using DMSO and prepared according 
to standards guidelines (NCCLS, 2008) to obtain a final 
concentration of 16 to 0.0313 µg/mL. Microplates were 
incubated at 35°C for 72 h to obtain the results of minimum 
inhibitory concentration (MIC). For minimum fungicidal 
concentration (MFC), 10 μl aliquots of the wells with no 
fungal growth were transferred to Petri dishes containing 
Sabouraud dextrose agar and incubated at 27 °C for 72 h to 
visualize fungal growth. All experiments were performed 
in duplicate. 
LogP calculation
The estimated logP was calculated using the software 
Marvin version 14.8.11, using the calculation plugin 
implemented in the software. The calculation method is 
based on the publication of Viswanadhan et al. (1989), 
which is weighted by Klopman method and Physprop 
database data. Considered electrolyte concentrations (Na+, 
K+ and Cl-) were 0.1 mol/L.
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Statistical analysis
Analysis of variance and comparison of geometric 
means were performed by the Kruskal-Wallis test. Data 
were analyzed using the statistical software BioEstat® 
(version 5.3), and a P value of 0.05 was considered 
significant. 
RESULTS
The five POA derivatives 1-5 (Figure 2) were 
prepared using the previously reported methodology 
from our group (Segretti et al., 2016), with moderate to 
good yields. The spectroscopic evaluation led to data in 
accordance with the literature. 
As can be seen in Table I, a variable antifungal 
activity among the POA and their derivatives 1-5 is noted, 
which the parent drug POA presented only weak or no anti-
Sporothrix spp. activity. However, the esterification of the 
carboxylic acid led to improved activity. In this way, the 
compounds 3 and 4 can be highlighted due to fungistatic 
and fungicidal activities against 100% of S. brasiliensis 
isolated from cats (6/6) and S. schenckii standard strain 
from a human. For compound 3, the antifungal activity 
values ranged from 2.12 to 1.06 mg/mL (MIC) and from 
4.24 to 1.06 mg/mL (MFC), whereas for compound 4 
ranged from 0.32 to 2.56 mg/mL (MIC) and from 1.29 
to 5.15 mg/mL (MFC). However, one S. brasiliensis 
standard strain from human (Ss177) was not sensitive to 
none compound. 
On the other hand, only 83.3% (5/6) of feline S. 
brasiliensis were sensitive to inhibitory activity of 2 (MIC 
from 3.06 to 0.77 mg/mL) and 5 (MIC from 2.9 to 0.05 
mg/mL), but a weak fungicidal activity was noted in only 
two feline isolates for both molecules, which the values 
of MFC on 50% and 90% of overall isolates (MFC50 
and MFC90, respectively) were >3.06 mg/mL for 2 and 
>2.90 mg/mL for 5. The remaining molecules were 
considered weakly active against S. brasiliensis (MIC50 and 
90 and MFC50 and 90 were >3.34 mg/mL for molecule 1 and 
>3.18 mg/mL for POA). 
Molecules 3 and 4 were the only active molecules 
on the overall microorganisms since the values of MIC90 
and MFC90 were 2.12 mg/mL and 4.24 mg/mL (for 3) 
and were 2.56 mg/mL and 5.15 mg/mL (for 4). The 
remaining molecules did not present this activity, showing 
values higher than the maximum concentration tested. 
Considering the overall Sporothrix spp. tested, 75% 
(6/8) were sensitive to the antifungal choice for therapy 
in human and animals, itraconazole (Table II). The cut-
off point was followed according to document M38-A2 
(NCCLS, 2008), in which fungal isolates with MIC values 
lower than or equal to 4 µg/mL are considered sensitive. 
On the other hand, two feline isolates showed MIC values 
ranging from 8 to >16 µg/mL and were then considered 
itraconazole-resistant isolates. 
DISCUSSION
POA is  considered the  act ive  form of  the 
tuberculostatic drug PZA, produced by PZA hydrolysis 
from a specific mycobacterial enzyme, PZAse (Zhang et 
al., 2003). PZA (and even POA) is especially active against 
the slow-growing intracellular M. tuberculosis, suggesting 
FIGURE 2 - Chemical structure of the pyrazinoic acid (POA) and their derivatives 1-5 evaluated in this work, and respective 
experimental values of partition coefficient (log P) as quantitative measure of the lipophilicity.
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that its action depends on some characteristics present in 
this subpopulation (Segretti et al., 2016). Although POA is 
the responsible for most of the observed effects of PZA, it 
cannot pass the mycobacterial membranes and thus it only 
possesses weak or no antimycobacterial activity. To improve 
its efficacy independently from the PZAse activation 
step, POA esters have been prepared and evaluated as 
antimycobacterial agents, showing very improved efficacy 
than POA (Fernandes et al., 2014; Segretti et al., 2016). On 
the other hand, POA and its ester derivatives do not show 
considerable activity against other bacteria.
Considering that mycobacteria and fungi (Willcocks, 
Wren, 2014) present some similarities (such as slow-
growing, the capacity of synthesizing threalose and 
inositol), we raised one question: Can POA and its 
derivatives be active against fungi? To answer this question 
in this work and taking advantage of the repositioning 
strategy (Ashburn and Thor, 2004; Corsello et al., 2017), 
we decided to explore the antifungal potential of these 
compounds against Sporothrix spp. clinical isolates from 
humans and animals with sporotrichosis. Considering that 
PZA can interfere in enzymes present in Leishmania that 
TABLE I - Minimal inhibitory concentration (MIC) and minimal fungicidal concentration (MFC) of different pyrazinoic acids 
(POA) molecules (mg/mL) to Sporothrix brasiliensis isolated from cats in Southern Brazila
Code b Host  
(Braz. State)
1 2 3 4 5 POA
MIC MFC MIC MFC MIC MFC MIC MFC MIC MFC MIC MFC
S68 Feline (RS) 0.83 0.83 0.77 0.77 1.06 2.12 1.29 1.29 0.73 0.73 1.59 3.18
S119 Feline (RS) 1.67 3.34 0.77 0.77 1.06 1.06 0.32 2.56 0.05 0.73 n.i. n.f.
S120 Feline (RS) n.i. n.f. n.i. n.f. 2.12 4.24 1.29 2.56 n.i. n.f. n.i. n.f.
S141 Feline (RS) n.i. n.f. 3.06 n.f. 2.12 2.12 2.56 2.56 2.9 n.f. n.i. n.f.
S144 Feline (RS) n.i. n.f. 3.06 n.f. 2.12 2.12 1.29 2.56 2.9 n.f. n.i. n.f.
S146 Feline (RS) 0.83 3.34 1.53 n.f. 2.12 2.12 1.29 2.56 2.9 n.f. n.i. n.f.
Ss177 c Human (RJ) n.i. n.f. n.i. n.f. n.i. n.f. n.i. n.f. n.i. n.f. n.i. n.f.
Ss126 c Human (SP) n.i. n.f. n.i. n.f. 2.12 4.24 2.56 5.15 n.i. n.f. n.i. n.f.
Overall d 50% n.i. n.f. 3.06 n.f. 2.12 2.12 1.29 2.56 2.9 n.f. n.i. n.f.
90% n.i. n.f. n.i. n.f. 2.12 4.24 2.56 5.15 n.i. n.f. n.i. n.f.
a Concentration range tested: 3.35-0.006 mg/mL (1 – Methyl pyrazinoate); 3.06-0.006 mg/mL (2 – Ethyl pyrazinoate); 4.24–0.008 mg/mL 
(3 – Butyl pyrazinoate); 5.15-0.01 mg/mL (4 – 2-Chloroethyl pirazynoate); 2.9-0.005 mg/mL (5 – 2(Pyrazinoyloxy)-ethyl pyrazinoate); 
3.18-0.006 mg/mL (POA – Pyrazinoic acid); b “S” strains are Sporothrix brasiliensis and belong to the culture collection of the Faculty of 
Veterinary, Federal University of Pelotas, UFPEL, RS, Brazil; c “Ss” strains belong to the culture collection of the Federal University of São 
Paulo (UNIFESP, SP, Brazil) – Ss177, Sporothrix brasiliensis standard strain (other codes: FMR 8314, Facultat de Medicina i Ciències de la 
Salut, Reus, Spain; IPEC 16968, Instituto de Pesquisa Evandro Chagas/FIOCRUZ, RJ, Brazil); Ss 126, Sporothrix schenckii standard strain; d 
50%, MIC/MFC at which 50% of overall isolates were inhibited/killed; 90%, MIC/MFC at which 90% of overall isolates were inhibited/killed. 
n.i.: no inhibitory activity at the concentrations tested; n.f.: no fungicidal activity at the concentrations tested.
TABLE II - Susceptibility of Sporothrix schenckii complex isolates to itraconazole (µg/mL) 
Sporothrix schenckii complex (n) Host Itraconazole (n)a
Sensitive Resistant Total
S. brasiliensis (6) b Feline (RS/Brazil) 4 2 6
S. brasiliensis (1) c Human (RJ/Brazil) 1 - 1
S. schenckii (1) c Human (SP/Brazil) 1 - 1
Overall (8) - 6 2 8
a Sensitivity (MIC ≤4 µg/mL) and resistance (MIC>4 µg/mL) defined according to the cut-off suggested by the M38-A2 (NCCLS, 
2008); b Clinical isolates from feline sporotrichosis belong to the culture collection of the Faculty of Veterinary, Federal University 
of Pelotas, UFPEL, RS, Brazil; c Standard strain from human sporotrichosis belong to the culture collection of the Federal University 
of São Paulo (UNIFESP, SP, Brazil) – Sporothrix brasiliensis (Ss177, other codes: FMR 8314, Facultat de Medicina i Ciències de 
la Salut, Reus, Spain; IPEC 16919, Instituto de Pesquisa Evandro Chagas/FIOCRUZ, RJ, Brazil); Sporothrix schenckii (Ss 126).
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have similar function than mycobacterial FASI (Mendez et 
al., 2009), by analogy it could also act in similar enzymes 
from fungi. To the best of our knowledge, this is the first 
report comprising the antifungal activity of POA and 
derivatives against this fungal microorganism.
The results showed that POA itself did not present 
important antifungal activity in the tested concentrations. 
This is probably due to a penetration issue through fungal 
cell membranes, which are considerably lipophilic. The 
ionization state of POA in the physiological pH difficult 
its penetration into the fungal cell, so the ester derivatives 
that do not ionize in this pH would improve the penetration 
and therefore the antifungal activity (Zhang et al., 2003; 
Fernandes et al., 2014). As can be noted in Table I, 
more lipophilic POA derivatives 1-4 have shown better 
antifungal activity. The more lipophilic (represented by 
logP values, Figure 2) the molecule, the higher antifungal 
activity. Compounds 3 (logP 1.05) and 4 (logP 0.39) 
showed the better anti-Sporothrix activity, exhibiting 
activity even in itraconazole-resistant isolates. The role of 
lipophilicity can be observed when comparing the activity 
of compounds 1 to 4, being 3 > 4 > 2 > 1. 
Interestingly, compound 5 is the more hydrophilic 
compound (logP –0.72) in the series, but it exhibited some 
anti-Sporothrix spp. activity. Compound 5 was designed 
as a double prodrug of POA, that after hydrolysis it will 
generate 2 moles-equivalent of POA instead of 1. It is 
a strategy to increase the intracellular concentration of 
POA, duplicating its efficacy (Segretti et al., 2016). In 
counterpart, the presence of two POA moieties leads to 
increased hydrophilicity, which limits the penetration of 5 
into the fungal cell. This can be the reason for the limited 
antifungal activity observed for this compound.
Although a more specific study must be done to 
determine the mechanism of POA derivatives’ action in 
fungi, the results suggest that esterification is necessary 
to POA exert its action inside the fungal cell. Since POA 
itself also presented poor activity in Sporothrix brasiliensis 
as observed previously to mycobacteria (Fernandes et al., 
2014; Segretti et al., 2016), it is possible that the esters 
must be hydrolyzed by cytoplasmic esterases, generating 
the active POA inside the fungal cell, in a similar way that 
was illustrated in Figure 1. However, it is also possible 
that the esters may exert fungistatic action per se, i.e. 
independently of the hydrolysis step. 
Regarding the S. brasiliensis tested, the S68 
and S119 isolates were sensitive to POA derivatives 
1–5; S141 and S144 were sensitive to 3 and 4 and 
both were inhibited by 2 and 5. In standards strains, S. 
schenckii (Ss126) was only sensitive to 3 and 4, and S. 
brasiliensis (Ss177) was not sensitive to any compounds 
tested. Although all these cited Sporothrix species were 
itraconazole-susceptible isolates, a difference in the 
profile of antifungal susceptibility was observed and 
probably is due to the virulence factors related to them, 
like melanin (Mario et al., 2016), and other factors still 
poorly understood. On the other hand, the itraconazole-
resistant isolates recognized in S120 and S146 were 
sensitive to 3 and 4, but only S146 was sensitive to 1 
and was inhibited to 2 and 5. The ability to resist to the 
action of itraconazole was also showed in S. brasiliensis 
isolated from feline and canine sporotrichosis (Waller et 
al., 2017), as well as in other Sporothrix species, such 
as S. albicans and S. luriei from feline and canine cases, 
respectively (Oliveira et al., 2011) and S. globosa from 
human sporotrichosis (Fischman Gompertz et al., 2016). 
In our study, the activity profile of POA derivatives in 
two itraconazole-resistant isolates (S120 and S146) shed 
light on the activity of these molecules. These isolates 
were only sensitive to inhibitory and fungicidal activities 
of 3 (MIC/MFC values 2.12–4.24 mg/mL) and 4 (MIC/
MFC values 1.29–2.56 mg/mL) molecules, indicating a 
probable alternative route of these compounds from the 
mechanism of action of itraconazole.
The main mode of action of itraconazole is the 
inhibition of lanosterol 14-α-demethylase (Kelly et al., 
1995) that is a key enzyme from the cytochrome P450 
family in the ergosterol biosynthesis (Borgers, Van de 
Ven, 1989). Ergosterol is a membrane sterol important 
for fungal integrity and maintenance. As consequence, 
the inhibition of this enzyme leads to the inhibition of the 
fungal growth. The inhibition of ergosterol biosynthesis 
together with the increased permeability of the fungal cell 
membrane by ergosterol deficiency, lead to morphological 
changes like abnormalities at the plasma membrane, 
the cell wall and cytoplasmic vacuoles, with defective 
cell division, abortive hyphal outgrowth and loss of cell 
viability (Borgers, Van de Ven, 1989). The activity of 
compounds 1-5 seems to be independent of lanosterol 
14-α-demethylase inhibition since their action occurs 
independently of the resistance. Maybe a similar role 
played in M. tuberculosis and L. major may be involved 
in this effect, however the mechanism of action for POA 
derivatives is still unknown.
This study demonstrates the potential of pyrazinoic 
acid and their derivatives as antifungal, which the most 
lipophilic molecules were active, including against 
itraconazole-resistant S. brasiliensis. The findings support 
potential usefulness of these molecules in the treatment of 
sporotrichosis and further studies should be undertaken 
to understand their mechanism of action and to evaluate 
their safe use.
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